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Background: Barrett’s esophagus (BE) may be managed by radiofrequency ablation, endoscopic mucosal resection (EMR), and surgical resection for
advanced lesions. The goal of this study was to evaluate the impact of EMR in patients referred for management of BE.
Methods: All patients referred to a tertiary center for management of BE between January 1, 2009 and August 7, 2012 were reviewed and stratiﬁed
according to dysplasia, Barrett’s-related neoplasm, and nodularity. Endpoints included histopathologic characterization of esophageal tissue biopsies and
EMR specimens, discrepancy between diagnoses, and subsequent change in management following EMR.
Results: In total, 2648 endoscopies were reviewed. Thirty-ﬁve patients having a total of 38 EMRs were included. Mucosal tissue biopsy and EMR
specimens were discordant in 24 of 38 specimens (63%). Of these, 20 biopsy results were upstaged (53%) and four downstaged (10.5%) following EMR. The
most common change was upstaging to invasive adenocarcinoma. EMR diagnosed 13 cases of invasive carcinoma, 12 of which were upstaged (92%). Based
on EMR results, management was changed in 13 cases (34%), primarily to surgery.
Conclusion: Mucosal biopsies and EMR results were discrepant in 63% of cases, with 53% resulting in an upstaged diagnosis. Approximately one-third of
these patients had a change in management. In patients referred for BE, EMR was found to be fundamental to accurate grading and should be a
component in the evaluation and management of Barrett-related lesions.
Copyright  2013, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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In consensus guidelines, radiofrequency ablation (RFA) with or
without endoscopic mucosal resection (EMR) is the recommended
management for patients with high-grade dysplasia (HGD).1 Non-
dysplastic Barrett’s esophagus and carcinoma arising in a back-
ground of Barrett’s esophagus are often managed with surveillance
and surgical resection, respectively. EMR is recommended for pa-
tients with Barrett’s esophagus with dysplasia with nodules or
mucosal irregularity. Many patients are referred for and undergo
treatment for Barrett’s esophagus and related lesions based on
mucosal forceps biopsies, despite studies showing that EMR and
biopsy results are frequently discordant.2–6
The aim of this study was to evaluate the cohort of patients
referred with Barrett’s esophagus to determine the impact of EMR
on the grading and subsequent management of the disease. We
sought to determine the frequency and nature of the discrepancy
between the mucosal forceps biopsy results and EMR results in
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impact of the EMR on change in management. These results should
be of use in understanding the impact and role of EMR in patients
referred for endoscopic management of Barrett’s esophagus.
Methods
Study design and population
This study was a single-center retrospective cohort study.
The study was approved by the Institutional Review Board of
Emory University, Atlanta, GA, USA. All patients provided informed
consent for esophagogastroduodenoscopy, EMR, endoscopic ultra-
sound, and/or RFA. The search involved patients receiving esoph-
agogastroduodenoscopy and/or endoscopic ultrasound within the
time period from January 1, 2009 to August 7, 2012. The initial
search resulted in 1672 patients, who underwent a total of 2648
endoscopic ultrasound and esophagogastroduodenoscopy pro-
cedures. This subset was restricted to patients who underwent ane, Atlanta, GA, USA
University School of Medicine, 1365 Clifton Road, NW, Building B, STE 1200, Atlanta,
on. Published by Elsevier. All rights reserved.
Table 1 Baseline Demographic Data in the Study Population of Patients
Referred for Management of Barrett’s Esophagus*
Characteristics N (%)
Gender
Male 27 (77)
Female 8 (23)
Age (y)
28–50 3 (9)
51–91 32 (91)
Mean 67
Ethnicity
Caucasian 28 (80)
African American 5 (14)
Other 2 (6)
Length of metaplasia (cm)
Short segment 21 (60)
Long segment 13 (37)
No metaplasia 1 (3)
* Data from 35 patients that participated in this review.
Table 2 Histopathologic Results of Biopsy Specimens Comparing Initial Forceps
Biopsy and Subsequent Endoscopic Mucosal Resection Characterizations
Tissue biopsy
result
EMR Result Total
No metaplasia Metaplasia LGD HGD IMC INV
Suspicious 3 1 0 1 2 1 8
IM 0 6 0 0 0 1 7
LGD 0 0 0 0 1 0 1
HGD 0 1 1 2 3 3 10
IMC 0 0 0 2 2 7 11
INV 0 0 0 0 0 1 1
Total 3 8 1 5 8 13 38
HGD, high-grade dysplasia; IM, intestinal metaplasia; IMC, intramucosal adeno-
carcinoma; INV, invasive adenocarcinoma; LGD, low-grade dysplasia; Suspicious,
suspicious for intestinal metaplasia.
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gastroesophageal junction were excluded. Patients without a prior
tissue biopsy were excluded. Prior biopsy results were obtained
from the study institution or the referring institution. Outside bi-
opsies were not reviewed by the internal institution’s pathologists.
Internal specimens (biopsy and EMR) were evaluated by two expert
pathologists. In the ﬁnal study set of patients, 38 esophageal and
gastroesophageal junction EMRs were performed. The subsequent
clinical course for patients following EMR was determined by a
review of their medical records. Results were not recorded if an
esophageal intervention (such as RFA) occurred between the tissue
biopsy and EMR.
Histologic result of the biopsy and EMR was recorded as no
evidence of metaplasia, Barrett’s esophagus/metaplasia, low-grade
dysplasia (LGD), HGD, intramucosal adenocarcinoma (IMC), or
invasive adenocarcinoma (INV). LGD was deﬁned as mild archi-
tectural complexity with cells having basilar pseudostratiﬁed and
hyperchromatic nuclei encroaching upon the glands.7 This set of
histologic features is often shared with the diagnosis of “indeﬁnite
for dysplasia,” inwhich the specimen has not met all the criteria for
a higher-grade classiﬁcation. They are often combined into one
category. In this study, specimens that were indeﬁnite for dysplasia
were excluded. If a patient had multiple grades on multiple bi-
opsies, the highest grade was used for that patient. HGD was
deﬁned as stratiﬁed, hyperchromatic nuclei with nuclear enlarge-
ment, and an increased nuclear-to-cytoplasmic ratio, with the
presence of prominent nucleoli, increased mitotic ﬁgures, and loss
of nuclear polarity.8 IMC was deﬁned as a neoplasm invading into
the lamina propria or muscularis muscosa without submucosal
invasion. INV was deﬁned as inﬁltrating neoplastic cells invading
the submucosa. Features may include intraluminal necrosis, abor-
tive microglands, or a continuous anastomosing gland pattern.9 For
both biopsy and EMR results, the highest histopathologic grade
assigned to a specimen by a reviewing pathologist was considered
to be the diagnosis. A downstage was deﬁned when the histologic
grade was lower on the EMR specimen than that from the prior
biopsy results. An upstage was deﬁned when the EMR results
characterized a more advanced histopathologic grade than the
prior biopsy result. The location and size of lesion for biopsy and
EMR were recorded. Short-segment Barrett’s esophagus was
deﬁned as an endoscopic length of less than 3 cm, whereas long-
segment Barrett’s esophagus was 3 cm or greater in length, as
measured endoscopically.
Clinical documentation was searched for treatment performed
prior to biopsy and EMR and after EMR, to identify all recommen-
dations for changes in management. Patient charts were also
reviewed following EMR to determine themanagement course that
was followed.
Results
Study results included data from 38 esophageal EMRs and pre-
ceding tissue biopsies from 35 patients. Three patients had two
recorded biopsies with a corresponding EMR, whereas the
remaining 32 patients had data from only one biopsy and EMR.
Patient ages ranged from 28 years to 91 years (mean, 67.06 years;
median, 67 years). The ethnicities included Caucasians (28), African
Americans (5), and other race patients (2). The results included data
from 21 patients with short-segment and 13 patients with long-
segment Barrett’s esophagus. Reﬂecting the referral population in
a tertiary care setting, 10 of the long-segment disease cases were
found to have INV. One patient was not found to havemetaplasia on
either biopsy or EMR (Table 1). The number of days between the
patient’s ﬁrst point of contact at the tertiary center and the last
documented point of contact was 440 days.Histologic characteristics of the mucosal biopsy and subsequent
EMR are compared in Table 2. The EMR histologic data yielded the
following diagnoses: three with no metaplasia, eight with Barrett’s
esophagus/metaplasia, one with LGD, ﬁve with HGD, eight with
IMC, and 13 with INV. The tissue biopsy and EMR results were
discordant in 24 of 38 specimens (63%). Of the biopsy results, 20
were upstaged (53%) and four were downstaged (10.5%) following
EMR (Table 2). In the remaining 14 (37%) cases, the biopsy and EMR
results were similar. In cases of discrepancy, EMR diagnosed IMC or
INV most commonly. Biopsy diagnosed eight cases showing no
metaplasia. These biopsies were taken from patients with a high
suspicion of Barrett’s esophagus and those who were being moni-
tored after a previous diagnosis of Barrett’s esophagus or carci-
noma. These specimens were collected at the same time as the EMR
specimens. Of these eight lesions, ﬁve (63%) were upstaged and
three (37%) were concordant with EMR. Biopsy identiﬁed seven
cases of nondysplastic Barrett’s esophagus, with one (14%) being
upstaged by EMR and six (86%) being concordant with EMR. The
one low-grade lesion diagnosed by tissue biopsy was upstaged by
EMR. Biopsy identiﬁed 10 high-grade lesions, of which six (60%)
were upstaged and two (20%) were downstaged by EMR, and two
(20%) were concordant with EMR. Tissue biopsy identiﬁed 11 IMC
lesions, with seven (64%) being upstaged and two (18%) down-
staged by EMR, and two (18%) being concordant with EMR. Tissue
biopsy diagnosed one lesion as INV, which was concordant with
EMR.
EMR detected more cases of IMC and INV than biopsy. Eight
cases of IMC were identiﬁed, with six (75%) being upstaged from
biopsy results and two (25%) being concordant with biopsy. Two of
the upstaged lesions were diagnosed as no metaplasia on biopsy,
showing major discordance with EMR. EMR diagnosed 13 cases of
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remaining one was concordant (8%). One of these preceding bi-
opsies showed no metaplasia and another showed nondysplastic
Barrett’s esophagus, indicating major discordance with EMR.
Fourteen patients were found to have esophageal nodules on
endoscopy, six with Barrett’s esophagus, one with LGD, two with
HGD, three with IMC, and two with INV.
In the 38 sets of specimens, 13 changes were made in the
management after diagnoses by EMR (34%; Table 3). RFA was per-
formed in 10 cases after EMR pathology results showed dysplasia.
Two patients were referred for cryoablation and 10 were referred
for surgery. All the cryoablation and surgery referrals followed an
EMR diagnosis of INV. Patients with INV undergoing ablative
therapy were not candidates for surgery due to comorbid condi-
tions. RFAwas performed in a total of 26 of the 35 patients (74.29%).
Discussion
The recommended management for patients with Barrett’s
esophagus with HGD without carcinoma is RFA with or without
EMR. EMR may be a better tool for the histopathologic character-
ization of disease in patients with Barrett’s esophagus, and we
sought to determine the impact of EMR on a cohort of patients
referred for Barrett’s esophagus management. There was a higher
proportion of neoplastic lesions and IMC reﬂecting the subset
referred to a tertiary care center for management. The study
demonstrated that mucosal forceps biopsies and EMR results were
discrepant in 63% of cases, with 53% resulting in an upstaged
diagnosis. In contrast to recommendations, these data do not sug-
gest that EMR should be an optional component in management.
Rather, EMR was fundamental to the accurate histopathologic
characterization of Barrett’s esophagus-related lesions and resulted
in a change in management in approximately one-third of the pa-
tients in the tertiary referral cohort.
Supporting these ﬁndings, studies have also shown that EMR is a
better diagnostic tool than mucosal biopsy for patients with Bar-
rett’s esophagus without nodules. Changes in diagnosis between
tissue biopsy and EMR have demonstrated rates varying from 20%
to 49%.5,9–11 The present study shows a higher degree of discor-
dance between specimens (in 63%). Many discrepancies were found
between biopsy and EMR results, with the former showing HGD
and IMC whereas the latter revealed intramucosal and invasive
cancer. In the present study, six of 10 HGD lesions were upstaged:
three to IMC and three to INV. Similarly, seven of 11 lesions diag-
nosed as intramucosal by biopsy were found to be invasive by EMR.
Findings suggesting cancer prompt a referral for surgical consul-
tation. The lesions that were upstaged to invasive cancer after EMR
corresponded to the largest and arguably the most important
discrepancy between biopsy and EMR results. Management was
changed for 12 of 13 patients in that group (92.31%), with a referral
for evaluation of esophagectomy. Two patients were not considered
to be surgical candidates despite the diagnosis and received salvage
cryoablation. One of the 13 management changes occurred when aTable 3 Changes inManagement of Patients with Discrepant Results fromPrior
Tissue Forceps Biopsy and Subsequent Endoscopic Mucosal Resection
Biopsy result EMR result Recommendation following EMR (N)*
HGD BE Intensive surveillance (1)
Suspicious for metaplasia INV Esophagectomy (1)
BE INV Esophagectomy (1)
HGD INV Esophagectomy (2), cryoablation (1)
IMC INV Esophagectomy (6), cryoablation (1)
BE, Barrett’s esophagus; HGD, high-grade dysplasia; IMC, intramucosal adenocar-
cinoma; INV, invasive adenocarcinoma.
* This column demonstrates the recommendation following the ﬁnal diagnosis
based on the EMR specimen.patient with HGD on biopsy was found to have nondysplastic
Barrett’s esophagus on EMR. This patient wasmonitored with serial
endoscopy and medical therapy instead of RFA.
From a treatment standpoint, EMR may also be useful. A large
study described data from October 1996 to September 2002 of 279
patients with HGD or IMC undergoing EMR. Patients with invasive
carcinoma were not involved due to the possibility of lymph node
metastases. They had extensive follow-up at 1 month, 2 months, 3
months, 6, and 9 months after treatment and then at 6-month in-
tervals for another 5 years. The eradication rate for these patients
was 94.5%. The rate of metachronous lesions requiring further
endoscopic intervention was 21.5%. Three of these patients under-
went surgery.12 In another study with 37 patients undergoing
stepwise EMR for HGD or early neoplasia, 89% had complete
eradicationwith 2% that experienced complications (asymptomatic
perforation and delayed bleeding).13 EMR has a clear role in the
treatment of dysplastic lesions and may potentially have a role in
the treatment of superﬁcial or intramucosal lesions in select sub-
sets of patients.
Of the 14 nodules resected by EMR, the histologic character-
ization was six nondysplastic Barrett’s lesions, two low-grade
dysplastic lesions, two high-grade dysplastic lesions, three IMCs,
and one invasive carcinoma. Thus, in this setting, Barrett’s nodules
had a high likelihood of advanced histology (57%). In a 2001 study,
the presence of a nodule was found to increase the likelihood of
submucosal invasion.14 However, nodules have also been identiﬁed
in overdiagnosis of esophageal neoplasia.15 Our data indicate that
EMR of Barrett’s nodules results in a high frequency of dysplastic
and malignant histopathologic characterizations, and that EMR is
themodality of choice for themanagement of nodules and irregular
mucosa. Long-segment disease was found to be associated with
more advanced histology, reﬂecting the most commonly affected
subset of the population16,17; most patients involved in the study
were Caucasian males (34; 89.47%).
This study had a number of limitations. Although the designwas
retrospective, it permitted observation of the change in manage-
ment based on the EMR results. The sample sizewasmoderate at 35
and reﬂected a highly selected subset of patients referred to a ter-
tiary care institution. The rate of advanced histology was much
higher in this cohort than would be expected in a typical Barrett’s
cohort. Nevertheless, examination of this referral cohort provided a
larger proportion of patients with advanced histology fromwhich a
change in management could be examined. Biopsies performed at
outside institutions were not over-read by pathologists at the study
institution, as the goal was to characterize the change in manage-
ment that occurred following EMR. The baseline state was that
established by the prior forceps biopsy and the revised state was
that established following histopathologic examination of the
specimen generated by EMR. If the patient had not been referred,
management would presumably have proceeded based on the
forceps biopsy result.
Until the revised publication of treatment recommendations in
2008, the recommended management for Barrett’s esophagus with
HGDwas surgical resection. With the relatively recent introduction
of RFA and the excellent outcomes with endoscopic management of
Barrett’s esophagus, the recommendedmanagement for LGD, HGD,
and IMC is changing. It may be possible to eliminate LGD in 91% of
patients and eliminate HGD in 81% of patients using RFA.18 Some
studies suggest that EMR may be an effective treatment modality
for IMC,9,11,12 and may especially be suited to the large cohort of
patients who are not surgical candidates. INV is in most cases best
managed with surgical resection. Thus, accurate characterization of
the pretreatment histology has become the critical determinant of
divergent treatment recommendations. In our study, EMR changed
the pathologic characterization in 63% of cases, and patients would
Michelle P. Clermont et al. / Endoscopic Mucosal Resection 93have been erroneously classiﬁed if forceps biopsies alone had been
used to guide management. These data suggest that EMR may
be less an optional component in the management of Barrett’s
esophagus and more a key determinant in the accurate character-
ization of patients’ baseline histology.
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